Pharming Group N.V. Research And Development Expense

Quick Answer

Pharming Group N.V. reported Research And Development Expense of $83.15 million for the year ending 2024.

  • Pharming Group N.V. showed an increase of +20.7% in Research And Development Expense from 2023 to 2024.
  • This data is from Pharming Group N.V.'s annual report (Form 10-K), filed with the SEC on April 3, 2025.
  • XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2018 to 2024), Pharming Group N.V.'s Research And Development Expense has grown by 187.9%.
  • Historical annual values: Fiscal year 2024: $83.15 million | Fiscal year 2023: $68.91 million | Fiscal year 2022: $52.53 million | Fiscal year 2021: $70.37 million | Fiscal year 2020: $38.52 million | Fiscal year 2019: $28.37 million | Fiscal year 2018: $28.88 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: